Somatropin Biopartners

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion / Notification [1] issued on	Commission Decision Issued [2] / amended on	Product Information affected [3]	Summary
IAIN/0010	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	03/03/2017		Annex II and PL	
PSUSA/2772/ 201509	Periodic Safety Update EU Single assessment - somatropin	13/05/2016	n/a		PRAC Recommendation - maintenance

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5520
Send a question via our website www.ema.europa.eu/contact

IB/0006/G	This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	03/12/2015	n/a		
IA/0008/G	This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or	16/11/2015	24/10/2016	Annex II	

	manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient				
IB/0007/G	This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation	19/10/2015	n/a		
IAIN/0005	C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location	26/02/2015	n/a		
PSUSA/2772/ 201403	Periodic Safety Update EU Single assessment - somatropin	06/11/2014	n/a		PRAC Recommendation - maintenance

IAIN/0004	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	27/10/2014	n/a		
II/0001	This type II variation concerned the provision of the final study report for the follow-up part BPLG-004-FUP of the clinical study BPLG-004, undertaken to further investigate the long-term safety and to provide further final height data. The requested variation proposed no amendments to the product information. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority	23/01/2014	n/a		The objective of the 2-year follow-up period of this study was to evaluate the long-term safety of LB03002 in pre-pubertal children and to further explore efficacy and safety endpoints by prolonged treatment with LB03002. For the comparative period (1st treatment year), patients were randomised to receive either weekly LB03002 or daily Genotropin injections. Patients completing the 12-month comparative period were given the option to participate in a 12-month extension period where all patients received LB03002 (2nd treatment year). Patients who completed the extension period were offered to continue treatment with LB03002 for another two years (follow-up period) or until final height (FH) was reached, whichever occurred first (3rd and 4th treatment year). The patient population consisted of 58 patients from India and 9 from Egypt who continued into the follow-up period. In children with GHD, Somatropin Biopartners at a dose of 0.5 mg/kg/week demonstrated non-inferior efficacy compared to daily Genotropin at an appropriate dose of 0.21 mg/kg/week during the initial active controlled 12-month treatment period. In addition, short- and long-term efficacy (up to 4 years) is comparable to that published for daily somatropin regimens using dosages within the range recommended for GHD children in the EU (0.175 – 0.245 mg/kg/week). It can be concluded that LB03002, at a dose of 0.5 mg/kg/week, produces the expected growth responses and growth patterns over time. Therefore, similar final height gain with LB03002 as compared to currently licensed daily somatropins can be expected.

					Most AEs were related to normal childhood diseases or could be attributed to the underlying disorder. Local tolerance does not raise special safety concerns, since only one patient suffered from injection site reactions in the 2-year follow-up period. No new or unexpected TEAEs or SAEs occurred in the 2-year follow-up period of study BPLG-004. LB03002 remains with a tolerable safety profile. In conclusion, the CHMP considers this specific post-authorisation measure (PAM) 03 to be fulfilled. No more data can be expected from study BPLG004-FUP. No concerns regarding efficacy or safety arise from the long-term data of this study. In order to obtain further long-term efficacy data in the future, the CHMP has encouraged the MAH to provide final height data as part of the PASS. During the 2-year follow-up no new adverse events occurred that would change the benefit/risk balance of Somatropin Biopartners. The results from the 2-year follow-up period of study BPLG-004 support the previously undertaken benefit/risk assessment and hence do not warrant any changes to the currently approved product information.
IAIN/0002	C.I.12 - Inclusion or deletion of black symbol and explanatory statements for medicinal products in the list of medicinal products that are subject to additional monitoring	13/12/2013	15/12/2014	SmPC, Annex II and PL	